date:Nov 30, 2012
ions as in its first Statement (EFSA 2012). The study as described by Sralini et al. does not allow giving weight to their results and conclusions as published. Conclusions cannot be drawn on the difference in tumour incidence between treatment groups on the basis of the design, the analysis and the results as reported. Taking into consideration Member States assessments and the authors answer to critics, EFSA finds that the study as reported by Sralini et al. is of insufficient scientific quali